We are live on ! Find out more
LAB icon

Standard BioTools
LAB

68 hedge funds and large institutions have $54.2M invested in Standard BioTools in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 22 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $42.5M → $54.2M (+$11.7M)

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

9.5% more ownership

Funds ownership: 49.12% → 58.62% (+9.5%)

5% more funds holding

Funds holding: 65 → 68 (+3)

18% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 22

65% less call options, than puts

Call options by funds: $37K | Put options by funds: $107K

Holders
68
Holders Change
+3
Holders Change %
+4.62%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
18
Reduced
22
Closed
11
Calls
$37K
Puts
$107K
Net Calls
-$70K
Net Calls Change
-$18K

Top Buyers

1
HBWM
Hollow Brook Wealth Management
New York
+$861K
2
HighTower Advisors
HighTower Advisors
Illinois
+$257K
3
Morgan Stanley
Morgan Stanley
New York
+$209K
4
JCP
Jennifer C. Price
+$146K
5
BCM
Bridgeway Capital Management
Texas
+$61.6K

Top Sellers

1
BlackRock
BlackRock
New York
-$712K
2
Primecap Management
Primecap Management
California
-$382K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$293K
4
PVI
Pura Vida Investments
New York
-$278K
5
E
Ergoteles
New York
-$220K
Name Holding Trade Value Shares
Change 		Change in
Stake
CP
1
Caligan Partners
New York
$10M +$10.6M +8,576,799 New
ICM
2
Indaba Capital Management
California
$8.71M – – –
Primecap Management
3
Primecap Management
California
$5.4M -$382K -310,070 -6%
Neuberger Berman Group
4
Neuberger Berman Group
New York
$5.11M -$14K -11,363 -0.3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$4.63M +$1.99K +1,614 +0%
NIM
6
Needham Investment Management
New York
$4.44M -$80K -65,000 -2%
Morgan Stanley
7
Morgan Stanley
New York
$3.57M +$209K +169,987 +6%
BFM
8
Boothbay Fund Management
New York
$2.69M – – –
BlackRock
9
BlackRock
New York
$1.65M -$712K -578,093 -29%
JCP
10
Jennifer C. Price
$1.14M +$146K +118,554 +14%
Millennium Management
11
Millennium Management
New York
$924K -$161K -130,592 -14%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$921K -$24.5K -19,936 -2%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$832K +$4.42K +3,591 +0.5%
HBWM
14
Hollow Brook Wealth Management
New York
$819K +$861K +699,611 New
HighTower Advisors
15
HighTower Advisors
Illinois
$534K +$257K +208,931 +85%
Renaissance Technologies
16
Renaissance Technologies
New York
$351K -$54.2K -44,000 -13%
State Street
17
State Street
Massachusetts
$330K – – –
BCM
18
Bridgeway Capital Management
Texas
$248K +$61.6K +50,000 +31%
Tudor Investment Corp
19
Tudor Investment Corp
Connecticut
$225K – – –
Northern Trust
20
Northern Trust
Illinois
$200K -$1.18K -955 -0.6%
CSS
21
Cubist Systematic Strategies
Connecticut
$181K +$49.5K +40,213 +35%
Rockefeller Capital Management
22
Rockefeller Capital Management
New York
$156K -$20.9K -17,000 -11%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$140K +$20.1K +16,344 +16%
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
$99K +$28.4K +23,100 +37%
Jane Street
25
Jane Street
New York
$86.2K +$59.7K +48,462 +192%
1
2 3 4

LAB Hedge Fund Activity: Q4 2022 in Review

68 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2022, worth a combined $54.2M — up 28% from $42.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LAB positions and 11 closed out — a net gain of 3 holders — while 18 added to existing stakes and 22 trimmed.

The largest buyer was Hollow Brook Wealth Management, opening a new position worth an estimated $861K. The largest seller was BlackRock, cutting an estimated $712K.

  • 68 institutional investors held Standard BioTools (LAB) as of Q4 2022, up from 65 in Q3 2022.
  • Funds reported $54.2M of Standard BioTools stock for Q4 2022, up 28% quarter-over-quarter.
  • 14 funds opened new Standard BioTools positions in Q4 2022 and 11 closed out, a net change of +3 holders.
  • The largest Standard BioTools buyer in Q4 2022 was Hollow Brook Wealth Management, an estimated $861K added.
  • The largest Standard BioTools seller in Q4 2022 was BlackRock, an estimated $712K sold.

Based on aggregated 13F filings for Q4 2022.